Target Name: PLAGL1
NCBI ID: G5325
Review Report on PLAGL1 Target / Biomarker Content of Review Report on PLAGL1 Target / Biomarker
PLAGL1
Other Name(s): OTTHUMP00000017348 | LOT1 | PLAGL1 variant 2 | ZAC1 | OTTHUMP00000017344 | DKFZp781P1017 | Tumor supressor ZAC | ZAC tumor supressor | tumor suppressor ZAC | OTTHUMP00000017347 | Zinc finger protein PLAGL1 (isoform 2) | PLAG1 like zinc finger 1 | Pleiomorphic adenoma-like protein 1 | Zinc finger protein PLAGL1 | MGC126276 | PLAG-like 1 | ZAC | LOT-1 | Lost on transformation 1 | OTTHUMP00000017345 | PLAG1 like zinc finger 1, transcript variant 3 | PLAL1_HUMAN | PLAG1 like zinc finger 1, transcript variant 2 | PLAGL1 variant 3 | pleiomorphic adenoma gene-like 1 | Tumor suppressor ZAC | OTTHUMP00000017346 | lost on transformation 1 | MGC126275 | Pleiomorphic adenoma gene-like protein 1 | Pleiomorphic adenoma gene-like 1

PLAGL1: Key Player in Proteasome System and Neurotransmitter Production

PLAGL1 (Proteasome-Lysine-30) is a protein that is expressed in various tissues throughout the body. It is a key player in the proteasome system, which is responsible for breaking down and degrading damaged or unnecessary proteins. PLAGL1 is highly expressed in the brain, and has been implicated in a number of neurological and psychiatric disorders.

One of the key functions of PLAGL1 is its role in the production of neurotransmitters, such as dopamine and serotonin. These neurotransmitters play a crucial role in the brain's communication system, and are involved in a wide range of physiological processes, including mood regulation, appetite, and sleep.

In addition to its role in neurotransmitter production, PLAGL1 is also involved in the regulation of pain. Studies have shown that PLAGL1 is expressed in the pain-producing neurons of the central nervous system, and that it plays a role in the development of pain sensitivity. This suggests that PLAGL1 may be a potential drug target for the treatment of pain disorders.

Another function of PLAGL1 is its role in the regulation of inflammation.PLAGL1 is expressed in the immune cells that are responsible for fighting off infections, and it is involved in the production of a type of immune response called an immune evasion response. This suggests that PLAGL1 may be a potential drug target for the treatment of autoimmune disorders.

PLAGL1 is also involved in the regulation of cell survival. Studies have shown that PLAGL1 is expressed in cancer cells, and that it plays a role in the development and progression of cancer. This suggests that PLAGL1 may be a potential drug target for the treatment of cancer.

In addition to its role in cancer and neurotransmission, PLAGL1 is also involved in the regulation of a wide range of physiological processes in the body. For example, it is involved in the production of the protein involved in the production of collagen, which is important for the formation of skin, hair, and other tissues. PLAGL1 is also involved in the regulation of the production of insulin, a hormone that helps regulate blood sugar levels.

Overall, PLAGL1 is a highly interconnected protein that is involved in a wide range of physiological processes in the body. Its role in the production of neurotransmitters, pain regulation, and inflammation makes it a potential drug target for the treatment of a wide range of disorders. Further research is needed to fully understand the functions of PLAGL1 and its potential as a drug target.

Protein Name: PLAG1 Like Zinc Finger 1

Functions: Acts as a transcriptional activator (PubMed:9722527). Involved in the transcriptional regulation of type 1 receptor for pituitary adenylate cyclase-activating polypeptide

The "PLAGL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLAGL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

PLAGL2 | Plasma Membrane Calcium ATPase | PLAT | Platelet Glycoprotein Ib Complex | Platelet-activating factor acetylhydrolase isoform 1B complex | Platelet-Derived Growth Factor (PDGF) | Platelet-Derived Growth Factor Receptor | PLAU | PLAUR | PLB1 | PLBD1 | PLBD1-AS1 | PLBD2 | PLCB1 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCD3 | PLCD4 | PLCE1 | PLCE1-AS2 | PLCG1 | PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin | PLG | PLGLA | PLGLB1 | PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4 | PLIN5 | PLK1 | PLK2 | PLK3 | PLK4 | PLK5 | PLLP | PLN | PLOD1 | PLOD2 | PLOD3 | PLP1 | PLP2